S&P 500   3,116.49 (+0.64%)
DOW   27,977.56 (+0.70%)
QQQ   202.50 (+0.53%)
CGC   15.44 (-2.53%)
BABA   185.38 (+1.41%)
GE   11.50 (+1.86%)
T   39.33 (+0.98%)
ACB   2.83 (-14.00%)
F   8.95 (+1.82%)
PRI   130.88 (+0.52%)
BAC   32.91 (+0.61%)
DIS   144.75 (-1.63%)
S&P 500   3,116.49 (+0.64%)
DOW   27,977.56 (+0.70%)
QQQ   202.50 (+0.53%)
CGC   15.44 (-2.53%)
BABA   185.38 (+1.41%)
GE   11.50 (+1.86%)
T   39.33 (+0.98%)
ACB   2.83 (-14.00%)
F   8.95 (+1.82%)
PRI   130.88 (+0.52%)
BAC   32.91 (+0.61%)
DIS   144.75 (-1.63%)
S&P 500   3,116.49 (+0.64%)
DOW   27,977.56 (+0.70%)
QQQ   202.50 (+0.53%)
CGC   15.44 (-2.53%)
BABA   185.38 (+1.41%)
GE   11.50 (+1.86%)
T   39.33 (+0.98%)
ACB   2.83 (-14.00%)
F   8.95 (+1.82%)
PRI   130.88 (+0.52%)
BAC   32.91 (+0.61%)
DIS   144.75 (-1.63%)
S&P 500   3,116.49 (+0.64%)
DOW   27,977.56 (+0.70%)
QQQ   202.50 (+0.53%)
CGC   15.44 (-2.53%)
BABA   185.38 (+1.41%)
GE   11.50 (+1.86%)
T   39.33 (+0.98%)
ACB   2.83 (-14.00%)
F   8.95 (+1.82%)
PRI   130.88 (+0.52%)
BAC   32.91 (+0.61%)
DIS   144.75 (-1.63%)
Log in

Insulet Stock Price, Forecast & Analysis (NASDAQ:PODD)

$179.60
+2.72 (+1.54 %)
(As of 11/15/2019 03:08 PM ET)
Today's Range
$176.97
Now: $179.60
$180.85
50-Day Range
$144.66
MA: $156.35
$177.54
52-Week Range
$70.80
Now: $179.60
$179.31
Volume17,897 shs
Average Volume805,566 shs
Market Capitalization$11.10 billion
P/E Ratio3,592.00
Dividend YieldN/A
Beta0.96
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:PODD
CUSIP45784P10
Phone978-600-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$563.82 million
Cash Flow$0.32 per share
Book Value$2.44 per share

Profitability

Net Income$3.29 million

Miscellaneous

Employees1,169
Market Cap$11.10 billion
Next Earnings Date2/24/2020 (Estimated)
OptionableOptionable

Receive PODD News and Ratings via Email

Sign-up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.


Insulet (NASDAQ:PODD) Frequently Asked Questions

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) posted its quarterly earnings results on Tuesday, November, 5th. The medical instruments supplier reported $0.01 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.03 by $0.02. The medical instruments supplier earned $192.12 million during the quarter, compared to analysts' expectations of $179.50 million. Insulet had a return on equity of 10.34% and a net margin of 2.38%. The firm's revenue for the quarter was up 27.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.03 EPS. View Insulet's Earnings History.

When is Insulet's next earnings date?

Insulet is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Insulet.

What price target have analysts set for PODD?

17 analysts have issued 1-year price targets for Insulet's shares. Their forecasts range from $100.00 to $185.00. On average, they anticipate Insulet's share price to reach $151.71 in the next twelve months. This suggests that the stock has a possible downside of 15.5%. View Analyst Price Targets for Insulet.

What is the consensus analysts' recommendation for Insulet?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 8 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insulet.

Has Insulet been receiving favorable news coverage?

Headlines about PODD stock have been trending somewhat negative recently, InfoTrie reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Insulet earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned news headlines about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Insulet.

Are investors shorting Insulet?

Insulet saw a increase in short interest in the month of October. As of October 15th, there was short interest totalling 5,230,000 shares, an increase of 11.0% from the September 15th total of 4,710,000 shares. Based on an average daily volume of 959,900 shares, the days-to-cover ratio is currently 5.4 days. Currently, 8.8% of the company's stock are sold short. View Insulet's Current Options Chain.

Who are some of Insulet's key competitors?

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include DexCom (DXCM), Tandem Diabetes Care (TNDM), Alibaba Group (BABA), NVIDIA (NVDA), Netflix (NFLX), Splunk (SPLK), salesforce.com (CRM), ServiceNow (NOW), EXACT Sciences (EXAS) and Veeva Systems (VEEV).

Who are Insulet's key executives?

Insulet's management team includes the folowing people:
  • Ms. Shacey Petrovic, Pres, CEO & Director (Age 45)
  • Mr. Charles Alpuche, Exec. VP & COO (Age 59)
  • Mr. Bret Christensen, Exec. VP & Chief Commercial Officer (Age 47)
  • Mr. Patrick J. Sullivan, Consultant (Age 67)
  • Mr. Michael L. Levitz, Advisor (Age 45)

Who are Insulet's major shareholders?

Insulet's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Eagle Asset Management Inc. (1.18%), Carillon Tower Advisers Inc. (0.87%), KAMES CAPITAL plc (0.62%), First Trust Advisors LP (0.43%), Columbus Circle Investors (0.38%) and Russell Investments Group Ltd. (0.33%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Institutional Ownership Trends for Insulet.

Which major investors are selling Insulet stock?

PODD stock was sold by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, KAMES CAPITAL plc, Chartwell Investment Partners LLC, C WorldWide Group Holding A S, Russell Investments Group Ltd., SG Americas Securities LLC, Essex Investment Management Co. LLC and Triodos Investment Management BV. Company insiders that have sold Insulet company stock in the last year include Aiman Abdel-Malek, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Insider Buying and Selling for Insulet.

Which major investors are buying Insulet stock?

PODD stock was bought by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Carillon Tower Advisers Inc., First Trust Advisors LP, Jag Capital Management LLC, Columbus Circle Investors, State of New Jersey Common Pension Fund D, California Public Employees Retirement System and Handelsbanken Fonder AB. View Insider Buying and Selling for Insulet.

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $179.60.

How big of a company is Insulet?

Insulet has a market capitalization of $11.10 billion and generates $563.82 million in revenue each year. The medical instruments supplier earns $3.29 million in net income (profit) each year or $0.05 on an earnings per share basis. Insulet employs 1,169 workers across the globe.View Additional Information About Insulet.

What is Insulet's official website?

The official website for Insulet is http://www.insulet.com/.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]


MarketBeat Community Rating for Insulet (NASDAQ PODD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  600 (Vote Outperform)
Underperform Votes:  526 (Vote Underperform)
Total Votes:  1,126
MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote "Outperform" if you believe PODD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PODD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Featured Article: Dividend Aristocrat Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel